Current Report Filing (8-k)
February 26 2015 - 10:40AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM 8-K
Current
Report
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): February 25, 2015
ProUroCare
Medical Inc.
(Exact
Name of Registrant as Specified in its Charter)
Nevada
|
000-51774
|
20-1212923
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
6440 Flying Cloud Dr., Suite 101, Eden Prairie, Minnesota
55344
|
(Address of Principal Executive Offices)(Zip Code)
|
(952)
476-9093
(Registrant’s
Telephone Number, Including Area Code)
Not
Applicable
(Former
Name or Former Address, if Changed Since Last Report)
Check the
appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any
of the following provisions:
⃞
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
⃞
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
⃞
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
⃞
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
1.01 Entry into a Material Definitive Agreement.
On February 25, 2015, ProUroCare Medical Inc. (“ProUroCare”) entered
into a Management Consulting Agreement (the “Agreement”) with Advanta
Management Consulting, Inc. (“Advanta”). The Company engaged Advanta to
provide operational, administrative and financial services to the
Company. Under the Agreement, the Company will provide a $85,000
retainer payment, $12,500 per month in consulting fees, and a 22.5%
equity stake in the Company if a minimum of $3,000,000 of needed working
capital is obtained through the efforts of Advanta. If minimum interim
funding, as defined in the agreement, is not received within 150 days
the Company may terminate the agreement with no obligation to provide
equity or any fees to Advanta. If the Company is unsuccessful in
obtaining $3,000,000 within 12 months, the Company has the option of
terminating the agreement and will have no obligation for the equity
stake and no further obligation for the retainer and monthly consulting
fees beyond any money raised through the date of termination.
SIGNATURES
Pursuant to
the requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
|
ProUroCare Medical Inc.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
By:
|
/s/ Stanton D. Myrum
|
|
|
|
|
Stanton D. Myrum
|
|
|
|
|
Chief Executive Officer
|
|
|
|
|
|
|
Date:
|
February 25, 2015
|
|
|
|
ProUroCare Medical (CE) (USOTC:PUMD)
Historical Stock Chart
From Oct 2024 to Nov 2024
ProUroCare Medical (CE) (USOTC:PUMD)
Historical Stock Chart
From Nov 2023 to Nov 2024